Close Menu

Venture capital firms are largely staying away from biotech, says Forbes' Bruce Booth. Reduced capital is a cyclical issue, and even with the problems in the biotech sector, bioentrepreneurs are still raising billions of dollars, he says. But what's really concerning is that the number of venture firms investing in biotech is shrinking and they're becoming less diverse.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.